

REGISTER OF INTERESTS

SIGN guideline: Migraine

Published:

26 September, 2025

	Financial		Non-financial		Non-personal	Any further declarations	Date received by SIGN Executive	Action
	<i>Specific</i>	<i>Non-Specific</i>	<i>Specific</i>	<i>Non-Specific</i>				
Dr Callum Duncan, Consultant Neurologist, NHS Grampian	None	None	<p>Advised on all 4 CGRP monoclonal antibodies – SMC – ceased – 2023.</p> <p>Advised on both Rimegepant and Atogepant – ceased - 2023.</p> <p>Contributed to review off Eptinezumab – NICE – ceased – 2023.</p> <p>Systematic review on preventative treatment for</p>	<p>Advised on Gammacore for Cluster Headache – SHTG – ceased – 2020.</p>	None	None	19.12.24	Waiver for participation agreed by SMT

REGISTER OF INTERESTS

SIGN guideline: Migraine

Published:

26 September, 2025

			<p>Chronic Migraine - University of Warwick - complete 2023.</p> <p>Funding requested for Systematic review on preventative treatment for Episodic Migraine – University of Warwick - Due to start September 2025 if successful.</p> <p>Book chapter on evidence based preventative treatment for migraine - Handbook of Clinical Neurology -</p>					
--	--	--	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--	--	--	--	--

REGISTER OF INTERESTS

SIGN guideline: Migraine

Published:

26 September, 2025

			complete 2023. Chair National Headache Pathway Group - Modernising Patient Pathways Program – current.					
Javier Carod Artal								
Dr Krishna Dani, Consultant Neurologist, NHS Greater Glasgow and Clyde	Talk to GPs on Rimegepant – Pfizer – Sept 25. Possible speaking engagement to GPs, for Abbvie, To be confirmed (Provisionally for October 22nd 2025) – Abbvie.	None	I was part for the last SIGN guideline update – SIGN. I was part of the development group for the Scottish National Headache Pathway – HIS – ongoing.	I am an Honorary Advisor for the full BASH Council - British Association for the Study of Headache (BASH) – ongoing.	None	None	09.08.25	Waiver for participation agreed by SMT

REGISTER OF INTERESTS

SIGN guideline: Migraine

Published:

26 September, 2025

	<p>Speaker on gepants data, European Headache Federation Conference (EHC) – Pfizer – Dec 25.</p> <p>Chair and Speaker at Forthcoming ‘Headstart’ Meeting – Teva – Oct 25.</p> <p>Advisory board on the theme of data gaps, forthcoming, June 2025 – Pfizer (one off).</p> <p>Speaker fees, Association of British</p>		<p>I am lead for the NHS GGC Headache Team and have been involved in developing local pathways – NHS GG&C – ongoing.</p> <p>I have reviewed CGRP medications (related to this review) for SMC.</p>					
--	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--	--	--	--	--

REGISTER OF INTERESTS

SIGN guideline: Migraine

Published:

26 September, 2025

	<p>Neurologists, May 2025 – Abbvie – one off.</p> <p>Speaker fees for Webinar; “Managing migraine through clinical cases” – Pfizer – one off.</p> <p>Speaker Fees received for Scottish Migraine Meeting lecture 2023 – Pfizer – one off.</p> <p>Speaker Fees received for Scottish Migraine Meeting lecture</p>							
--	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--	--	--	--	--	--	--

REGISTER OF INTERESTS

SIGN guideline: Migraine

Published:

26 September, 2025

	<p>November 2024 – Pfizer.</p> <p>Speaker Fees Received for Migraine Trust Lecture. Travel, accommodation, and conference registration was also included as part of this - Pfizer – ceased one off.</p> <p>Speaker Fees for lecture to GP Practice – Pfizer – ceased one off.</p> <p>Attendance at speaker</p>							
--	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--	--	--	--	--	--	--

REGISTER OF INTERESTS

SIGN guideline: Migraine

Published:

26 September, 2025

	<p>training meeting – fees may be received for this in due course – Abbvie – one off – fees not received yet.</p> <p>Speaker fees for lecture at the Association of British Neurologists may 2024. Travel and conference registration was also included as part of this – Abbvie – one off.</p> <p>Fees for contribution to digital advisory board 2023-2024 –</p>							
--	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--	--	--	--	--	--	--

REGISTER OF INTERESTS

SIGN guideline: Migraine

Published:

26 September, 2025

	<p>Abbvie – ceased 2024.</p> <p>Lundbeck Speaker fees at product launch 2023 – Lundbeck – one off.</p> <p>Fees for contribution to educational advisory board for HEADSTART meeting – TEVA – ceased – one off.</p> <p>Speaker fees for chairing the HEADSTART meeting 2024 - TEVA – ceased – one off.</p>							
--	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--	--	--	--	--	--	--

REGISTER OF INTERESTS

SIGN guideline: Migraine

Published:

26 September, 2025

	<p>Funding to attend sponsored Educational meeting, Prague, 2023 - TEVA – ceased – one off.</p> <p>Lecture to National Migraine Centre on Eptinezumab – Lundbeck – one off.</p> <p>Reimbursement for preparation time for a lecture which was subsequently cancelled – Lundbeck – one off.</p> <p>Travel, accommodation and</p>							
--	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--	--	--	--	--	--	--

REGISTER OF INTERESTS

SIGN guideline: Migraine

Published:

26 September, 2025

	registration for the European Headache Federation Conference in Barcelona December 2023 – Abbvie – ceased – one off.							
Arlene Coulson								
Anne Keane, Lay Representative, Edinburgh	Occasional freelance educational inspector (overseas) for the World Federation of Medical Education. Reviewer of draft curriculum for new postgraduate course,	None	None	None	None	None	31.8.25	

REGISTER OF INTERESTS

SIGN guideline: Migraine

Published:

26 September, 2025

	University of Liverpool.							
Dr Iain Maltman, Neurology Specialty Registrar, NHS Lothian	None	None	Myself Personal history of migraine headaches – ongoing.	None	None	None	2.9.25	No action required.
Mireia Moragas, Consultant Neurologist, NHS Lothian	None	None	I am a principal investigator for an observational study on patients starting Atogepant funded by Abbvie, I do not receive monetary retribution but our research facility is paid a fee for participating.	None	None	None	1.9.25	No action required.
Dr David Watson, GPwER in	Advisory Boards re GP education on	None	British Association for the Study	None	None	None	1.9.25	

REGISTER OF INTERESTS

SIGN guideline: Migraine

Published:

26 September, 2025

<p>Headache, NHS Grampian</p>	<p>27.6.22, 28.11.22,, 5.12.23 , 10.3.25 lecture fees for GP - Pfizer - education meetings ongoing.</p> <p>Educational boards on GP headache education 3.10.22, 6.1.23,8.1.24 ,12.3.25 lecture fees for GP educational meetings - AbbVie - on going.</p> <p>TEVA advisor board GP headache education August 25.</p>		<p>of Headache, Honorary adviser – current.</p> <p>Working on HEADPain study looking at CPRD aurum data base in England – Pfizer - current.</p> <p>European Migraine and Headache Alliance: helping with a research project – current.</p> <p>Family members including myself have migraine.</p>					
---------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--	--	--	--	--

REGISTER OF INTERESTS

SIGN guideline: Migraine

Published:

26 September, 2025

	<p>will be co chair of a GP educational meeting in November.</p> <p>Neurology Alliance. I have been asked to speak in November at a meeting on the pharmacy project we did and also take part in a small table forum on streamlining neurology services for headache.</p>							
--	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--	--	--	--	--	--	--